For 2022 full year guidance, the Company estimates revenues between $375 million and $385 million, Adjusted EBITDA between $201 million and $207 million and Adjusted non-GAAP earnings per diluted share of between $5.36
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) shares fell almost 20% after Scorpion Capital filed a Citizen's Petition with the FDA requesting the withdrawal of approval of Wakix (pitolisant).